Linked Life Data

7687532

Source:http://linkedlifedata.com/resource/pubmed/id/7687532

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1993-8-25
pubmed:abstractText
Antibody to hepatitis C virus (Anti-HCV) was examined in sera of 416 patients with hepatocellular carcinoma (HCC). The prevalence of anti-HCV was 11.1% (46/416), among them, the dual infection rate with HCV and HBV was 5.8% (24/416), in contrast to 2.0% (2/100) in blood donors. Moreover, sera of 38 patients with HCC accompanying with acute hepatitis were tested for anti-HAV, HBsAg and anti-HCV. Their positive rates were: hepatitis A 5.3% (2/38), hepatitis B 76.3% (29/38), hepatitis C 10.5% (4/38), and other hepatitis 7.9% (3/38), respectively. These results indicate that HBV infection seems to be more important than HCV infection in the etiology of HCC in our country. The role of HCV in the development of HCC remains to be further investigated.
pubmed:language
chi
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0253-3766
pubmed:author
pubmed:issnType
Print
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
44-6
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
[Prevalence of anti-HCV in sera of patients with hepatocellular carcinoma].
pubmed:affiliation
Liver Cancer Institute, Shanghai Medical University.
pubmed:publicationType
Journal Article, English Abstract